General MedicationsORALStandard
LENVATINIB
LENVATINIB MESYLATE
Standard Dose
10MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: Prescription
Summary
Approval overview LENVATINIB is listed in Drugs@FDA under application 213092 (ANDA).
Review priority: STANDARD Marketing status: Prescription Active ingredient LENVATINIB MESYLATE Form and strength CAPSULE; ORAL - 10MG Sponsor SUN PHARM INDS INC Submission history Latest submission status date: 2022-03-01 00:00:00.
Structured Monograph
Clinical summary
Approval overview LENVATINIB is listed in Drugs@FDA under application 213092 (ANDA). Review priority: STANDARD Marketing status: Prescription Active ingredient LENVATINIB MESYLATE Form and strength CAPSULE; ORAL - 10MG Sponsor SUN PHARM INDS INC Submission history Latest submission status date: 2022-03-01 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: Prescription
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.